Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
Crossref DOI link: https://doi.org/10.1007/s12325-017-0479-x
Published Online: 2017-01-20
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ravasio, Roberto
Text and Data Mining valid from 2017-01-20
Article History
Received: 10 January 2017
First Online: 20 January 2017